WIXOM, Mich., March 20, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the
"Company") today announced that Stuart Paul, Chief Executive Officer, will present at the Sidoti & Company LLC Spring 2019 Investor
Conference as follows:
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the
Company’s website at www.rockwellmed.com, under the “Investors” section.
To schedule a one-on-one meeting with management, please contact Sidoti & Company LLC at https://sidoti-company-spring-conference.events.issuerdirect.com/, or Lisa Wilson at lwilson@insitecony.com.
About Rockwell Medical, Inc.
Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD). Rockwell
Medical’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis
patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient
convenience. Rockwell Medical’s anemia drug Triferic is the only FDA-approved product indicated for iron replacement and
maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in
delivering high-quality hemodialysis concentrates/dialysates (used to maintain human life by removing toxins and replacing critical
nutrients in the dialysis patient’s bloodstream) to dialysis providers and distributors in the U.S. and abroad. Please visit
www.rockwellmed.com for more information.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
